Applied Biosystems Selects Medical Solutions Geneservice to be UK Service Provider for SNPlex™ Genotyping System
News Aug 21, 2007
The Board of Medical Solutions plc has announced that its recently acquired genomic services and products business Geneservice Limited has been chosen by Applied Biosystems to be the UK service provider of its SNPlex™ Genotyping System and help broaden access to its genotyping technology.
• Geneservice to benefit from marketing and technical support.
• Geneservice was selected because of its proven proficiency in executing the SNPlex™ chemistry workflow.
• SNPlex™ platform will enhance Geneservices’ delivery of advanced genotyping services.
As part of Applied Biosystems’ SNPlex™ Service Provider Program, Geneservice will benefit from marketing and technical support - which is expected to enhance its ability to deliver advanced genotyping services to its clients.
Geneservice will use the Applied Biosystems’ SNPlex™ technology and genotyping and sequencing platforms to offer a system for projects needing to genotype multiple single nucleotide polymorphisms (SNPs) from hundreds or thousands of samples.
The SNPlex™ Service Provider Program is intended to enable researchers who do not have access to capillary electrophoresis (CE) genetic analysis instrumentation to obtain a flexible and bespoke high-throughput SNP genotyping data solution.
Nick Leaves, Head of Operations for Medical Solutions said: "The SNPlex™ Genotyping System is well suited to the candidate gene association studies that typically follow whole-genome screening. We already have significant expressions of interest in SNPlex™ and have completed over 900,000 custom SNP genotypes in recent months. We are delighted to have had our experience recognised by Applied Biosystems and to have been chosen as its partner for this technology in the UK.”
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.